Open AccessAnticoagulation Therapy for Portal Vein Thrombosis in Patients with Cirrhosis in a Tertiary Center Experience
Author(s) -
Marieta Madalina Florescu,
Adrian Costache,
Speranţa Iacob,
Corina Pietrăreanu,
Carmen Ester,
Răzvan Cerban,
Radu Dumitru,
Mugur Grasu,
Ioana Gabriela Lupescu,
Liana Gheorghe
Publication year - 2021
Publication title -
journal of gastrointestinal and liver diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.641
H-Index - 48
eISSN - 1842-1121
pISSN - 1841-8724
DOI - 10.15403/jgld-3392
Subject(s) - medicine , portal vein thrombosis , vitamin k antagonist , antithrombotic , thrombosis , low molecular weight heparin , thrombus , cirrhosis , gastroenterology , retrospective cohort study , anticoagulant , deep vein , surgery , warfarin , atrial fibrillation
The evidence regarding the use of anticoagulant (AC) agents in portal vein thrombosis (PVT) is increasing and, most patients undergo chronic treatment with low molecular weight heparin (LMWH) or vitamin K antagonists (VKA). Nevertheless, there are no clear data about who should receive antithrombotic therapy, when to initiate it, how long and what dose should be used for this set of patients. The aim of the study was to assess the outcome of patients with cirrhosis and portal vein thrombosis who received AC therapy, in terms of thrombus regression, bleeding events and survival rates.